237 related articles for article (PubMed ID: 35830932)
1. Current Definitions and Clinical Implications of Biomarkers in Graft-versus-Host Disease.
Bidgoli A; DePriest BP; Saatloo MV; Jiang H; Fu D; Paczesny S
Transplant Cell Ther; 2022 Oct; 28(10):657-666. PubMed ID: 35830932
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD.
Vigorito AC; Campregher PV; Storer BE; Carpenter PA; Moravec CK; Kiem HP; Fero ML; Warren EH; Lee SJ; Appelbaum FR; Martin PJ; Flowers ME;
Blood; 2009 Jul; 114(3):702-8. PubMed ID: 19470693
[TBL] [Abstract][Full Text] [Related]
3. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIb. The 2020 Preemptive Therapy Working Group Report.
Pidala J; Kitko C; Lee SJ; Carpenter P; Cuvelier GDE; Holtan S; Flowers ME; Cutler C; Jagasia M; Gooley T; Palmer J; Randolph T; Levine JE; Ayuk F; Dignan F; Schoemans H; Tkaczyk E; Farhadfar N; Lawitschka A; Schultz KR; Martin PJ; Sarantopoulos S; Inamoto Y; Socie G; Wolff D; Blazar B; Greinix H; Paczesny S; Pavletic S; Hill G
Transplant Cell Ther; 2021 Aug; 27(8):632-641. PubMed ID: 33836313
[TBL] [Abstract][Full Text] [Related]
4. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report.
Paczesny S; Hakim FT; Pidala J; Cooke KR; Lathrop J; Griffith LM; Hansen J; Jagasia M; Miklos D; Pavletic S; Parkman R; Russek-Cohen E; Flowers ME; Lee S; Martin P; Vogelsang G; Walton M; Schultz KR
Biol Blood Marrow Transplant; 2015 May; 21(5):780-92. PubMed ID: 25644957
[TBL] [Abstract][Full Text] [Related]
5. Chronic graft-versus-host disease: implications of the National Institutes of Health consensus development project on criteria for clinical trials.
Pavletic SZ; Lee SJ; Socie G; Vogelsang G
Bone Marrow Transplant; 2006 Nov; 38(10):645-51. PubMed ID: 16980994
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Elafin as a Prognostic Biomarker in Acute Graft-versus-Host Disease.
Zewde MG; Morales G; Gandhi I; Özbek U; Aguayo-Hiraldo P; Ayuk F; Baez J; Chanswangphuwana C; Choe H; DeFilipp Z; Etra A; Grupp S; Hexner EO; Hogan W; Javorniczky NR; Kasikis S; Kitko CL; Kowalyk S; Meedt E; Merli P; Nakamura R; Qayed M; Reshef R; Rösler W; Schechter T; Weber D; Wölfl M; Yanik G; Young R; Levine JE; Ferrara JLM; Chen YB
Transplant Cell Ther; 2021 Dec; 27(12):988.e1-988.e7. PubMed ID: 34474163
[TBL] [Abstract][Full Text] [Related]
7. Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report.
Shulman HM; Kleiner D; Lee SJ; Morton T; Pavletic SZ; Farmer E; Moresi JM; Greenson J; Janin A; Martin PJ; McDonald G; Flowers ME; Turner M; Atkinson J; Lefkowitch J; Washington MK; Prieto VG; Kim SK; Argenyi Z; Diwan AH; Rashid A; Hiatt K; Couriel D; Schultz K; Hymes S; Vogelsang GB
Biol Blood Marrow Transplant; 2006 Jan; 12(1):31-47. PubMed ID: 16399567
[TBL] [Abstract][Full Text] [Related]
8. Validation of National Institutes of Health global scoring system for chronic graft-versus-host disease (GVHD) according to overall and GVHD-specific survival.
Moon JH; Sohn SK; Lambie A; Ellis L; Hamad N; Uhm J; Gupta V; Lipton JH; Messner HA; Kuruvilla J; Kim D
Biol Blood Marrow Transplant; 2014 Apr; 20(4):556-63. PubMed ID: 24447907
[TBL] [Abstract][Full Text] [Related]
9. Application of proteomics to graft-versus-host disease: from biomarker discovery to potential clinical applications.
Presland RB
Expert Rev Proteomics; 2017 Nov; 14(11):997-1006. PubMed ID: 28974115
[TBL] [Abstract][Full Text] [Related]
10. [2018 update on chronic graft-versus-host disease].
Inamoto Y
Rinsho Ketsueki; 2018; 59(10):2300-2306. PubMed ID: 30305539
[TBL] [Abstract][Full Text] [Related]
11. Toward a Better Understanding of the Atypical Features of Chronic Graft-Versus-Host Disease: A Report from the 2020 National Institutes of Health Consensus Project Task Force.
Cuvelier GDE; Schoettler M; Buxbaum NP; Pinal-Fernandez I; Schmalzing M; Distler JHW; Penack O; Santomasso BD; Zeiser R; Angstwurm K; MacDonald KPA; Kimberly WT; Taylor N; Bilic E; Banas B; Buettner-Herold M; Sinha N; Greinix HT; Pidala J; Schultz KR; Williams KM; Inamoto Y; Cutler C; Griffith LM; Lee SJ; Sarantopoulos S; Pavletic SZ; Wolff D
Transplant Cell Ther; 2022 Aug; 28(8):426-445. PubMed ID: 35662591
[TBL] [Abstract][Full Text] [Related]
12. Design and Patient Characteristics of the Chronic Graft-versus-Host Disease Response Measures Validation Study.
Chronic GVHD Consortium
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1727-1732. PubMed ID: 29476954
[TBL] [Abstract][Full Text] [Related]
13. EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment.
Schoemans HM; Lee SJ; Ferrara JL; Wolff D; Levine JE; Schultz KR; Shaw BE; Flowers ME; Ruutu T; Greinix H; Holler E; Basak G; Duarte RF; Pavletic SZ;
Bone Marrow Transplant; 2018 Nov; 53(11):1401-1415. PubMed ID: 29872128
[TBL] [Abstract][Full Text] [Related]
14. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
15. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report.
Jagasia MH; Greinix HT; Arora M; Williams KM; Wolff D; Cowen EW; Palmer J; Weisdorf D; Treister NS; Cheng GS; Kerr H; Stratton P; Duarte RF; McDonald GB; Inamoto Y; Vigorito A; Arai S; Datiles MB; Jacobsohn D; Heller T; Kitko CL; Mitchell SA; Martin PJ; Shulman H; Wu RS; Cutler CS; Vogelsang GB; Lee SJ; Pavletic SZ; Flowers ME
Biol Blood Marrow Transplant; 2015 Mar; 21(3):389-401.e1. PubMed ID: 25529383
[TBL] [Abstract][Full Text] [Related]
16. Role of cytokines in the pathophysiology of acute graft-versus-host disease (GVHD): are serum/plasma cytokines potential biomarkers for diagnosis of acute GVHD following allogeneic hematopoietic cell transplantation (Allo-HCT)?
Toubai T; Tanaka J; Paczesny S; Shono Y; Reddy P; Imamura M
Curr Stem Cell Res Ther; 2012 May; 7(3):229-39. PubMed ID: 22023620
[TBL] [Abstract][Full Text] [Related]
17. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report.
DeFilipp Z; Couriel DR; Lazaryan A; Bhatt VR; Buxbaum NP; Alousi AM; Olivieri A; Pulanic D; Halter JP; Henderson LA; Zeiser R; Gooley TA; MacDonald KPA; Wolff D; Schultz KR; Paczesny S; Inamoto Y; Cutler CS; Kitko CL; Pidala JA; Lee SJ; Socie G; Sarantopoulos S; Pavletic SZ; Martin PJ; Blazar BR; Greinix HT
Transplant Cell Ther; 2021 Sep; 27(9):729-737. PubMed ID: 34147469
[TBL] [Abstract][Full Text] [Related]
18. Use of the NIH consensus criteria in cellular and soluble biomarker research in chronic graft-versus-host disease: A systematic review.
Milosevic E; Babic A; Iovino L; Markovic M; Grce M; Greinix H
Front Immunol; 2022; 13():1033263. PubMed ID: 36389657
[TBL] [Abstract][Full Text] [Related]
19. Plasma biomarkers in graft-versus-host disease: a new era?
Paczesny S; Levine JE; Braun TM; Ferrara JL
Biol Blood Marrow Transplant; 2009 Jan; 15(1 Suppl):33-8. PubMed ID: 19147075
[TBL] [Abstract][Full Text] [Related]
20. Recognizing and managing chronic graft-versus-host disease.
Lee SJ; Flowers ME
Hematology Am Soc Hematol Educ Program; 2008; ():134-41. PubMed ID: 19074071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
